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Piotr Podolec, MD, PhD1, and Maria Olszowska, MD, PhD1
Abstract
The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the
coagulation cascade. We evaluated the levels of platelet- (CD42b) and endothelial-derived (CD144) microparticles in the plasma
patients with non-valvular AF treated with dabigatran at the time of expected minimum and maximum drug plasma concentra-
tions. Following that, we determined the peak dabigatran plasma concentration (cpeak ). CD42b increased after taking dabigatran
(median [IQR] 36.7 [29.4-53.3] vs. 45.6 [32.3-59.5] cells/mL; p ¼ 0.025). The concentration of dabigatran correlated negatively
with the post-dabigatran change in CD42b (DCD42b, r¼ -0.47, p¼ 0.021). In the multivariate model, the independent predictors
of DCD42b were: cpeak (HR -0.55; with a 95% confidence interval, CI [-0.93, -0.16]; p ¼ 0.007), coronary artery disease (CAD)
(HR -0.41; 95% CI [-0.79, -0.02]; p¼ 0.037) and peripheral artery disease (PAD) (HR 0.42; 95% CI [0.07, 0.74]; p¼ 0.019). CD144
did not increase after dabigatran administration. These data suggest that low concentrations of dabigatran may be associated with
platelet activation. PAD and CAD have distinct effects on CD42b levels during dabigatran treatment.
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Introduction
Atrial fibrillation (AF) remains the most common cardiac
arrhythmias in clinical practice, which is associated with an
increased risk of stroke and systemic embolism. AF itself
enhances endothelial dysfunction, platelet aggregation and
coagulation.1,2 Dabigatran, a non-vitamin K oral anticoagulant
(NOAC) specifically and reversibly blocks the activity of
thrombin, exerting direct antithrombotic and indirect anti-
platelet action.3,4 Effective anticoagulant treatment with
NOACs such as dabigatran is an essential process for improv-
ing the prognosis of patients with AF.5,6
Circulating microparticles (MPs) are membrane vesicles
that are <2 mm in size, which are released into the plasma from
all morphotic blood elements and the vascular endothelium
through exotic budding of the plasma membrane in response
to cellular apoptosis or activation.7 MPs have surface antigens
characteristic of the cells from which they were made. MPs
play a crucial role in haemostasis and thrombosis.8,9
MPs derived from platelets (PMPs) and endothelial-derived
MPs (EMPs) participate in coagulation and haemostasis by
inducing platelet aggregation or developing platelet and fibrin
rich thrombi.7 Circulating procoagulant MPs might reflect a
hypercoagulable state that contributes to arterial thromboem-
bolism.10,11 Circulating EMPs have been linked to the severity,
lesion volume, and outcome of acute ischemic stroke.12 Some
medications, such as antihypertensives, lipid-lowering agents
and antioxidant drugs modulate PMP and EMP levels.13-16
1 Department of Cardiac and Vascular Diseases, Institute of Cardiology, Faculty
of Medicine, Jagiellonian University Medical College, John Paul II Hospital,
Cracow, Poland
2 Department of Pharmacology, Jagiellonian University Medical College,
Cracow, Poland
Corresponding Author:
Aleksandra Lenart-Migdalska, Department of Cardiac and Vascular Diseases,










Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access
pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recent clinical findings suggest that MPs may play a role in
the hypercoagulable state in AF.10,17-19 Previous studies13 have
showed increased levels of PMPs and EMPs in patients with
AF, indicating elevated endothelial damage and platelet activa-
tion. Moreover, PMPs have been reported to be used for mon-
itoring antithrombotic therapy in patients with type 2
diabetes.20,21
The aim of this study was to evaluate the levels of PMPs and
EMPs, namely platelet glycoprotein Ib (GPIb, cluster of differ-
entiation 42b, CD42b) and vascular endothelial cadherin
(VE-cadherin, CD144), respectively, in patients with non-
valvular AF treated with dabigatran.
Material and Methods
Design
In this prospective observational study, we evaluated patients
with non-valvular AF treated with dabigatran etexilate (dabi-
gatran). According to the protocol of the study, we have deter-
mined in-plasma peak dabigatran and microparticle (CD42b
and CD144) concentrations at the time of expected minimum
and maximum dabigatran concentrations. The trough sample
was obtained at 12 hours after taking the drug. The post-dose
samples were collected 1 to 3 hours after drug ingestion.
Study Patients
After giving their informed consent, a total of 39 patients with
documented AF treated with dabigatran for 3 months or more
who were screened in our department between August 2015 to
August 2017, were enrolled in the study. The exclusion criteria
were unstable cardiovascular diseases (unstable coronary
artery disease [CAD], exacerbation of chronic heart failure,
uncontrolled hypertension), recent (<3 months) thromboem-
bolic events (stroke/TIA or systemic embolism), connective
tissue disease, uncontrolled thyroid disease and chronic kidney
disease stage 4 or more.22
The CHA2DS2-VASc score was used to evaluate the risk of
stroke or systemic embolism.23 The patients’ bleeding risk was
estimated using the HAS-BLED score.24
Patients were evaluated at enrollment for dabigatran dosage
based on current guidelines.5 We used a standardized question-
naire to collect the patients’ demographics data, information
about cardiovascular risk factors and current treatment.22
Patients were monitored for 12 months for cases of stroke and
systemic embolism, as well as major bleeding. The comorbid-
ities were defined in the Online supplemental material.
Blood Collection and Laboratory Analysis
Dabigatran plasma measurement. Plasma samples were collected
in Monovette ® vacuum tubes (S-Monovette, Sarstedt), con-
taining 3.2% trisodium citrate (10:1). Plasma concentrations of
dabigatran were determined with the BCS XP Automated
Blood Coagulation Analyzer System (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany), using
Hyphen BioMed products (Neuville Sur Oise, France), as per
the manufacturer’s instructions.25
Reference Ranges
The therapeutic ranges have not been clearly defined for
NOACs. Using the Randomized Evaluation of Long Term
Anticoagulant Therapy With Dabigatran Etexilate (RE-LY)
study26, we defined the “peak range” in the post-dose samples
for dabigatran at a given dose. The estimated total dabigatran
plasma concentrations after oral administration of 110mg or
150 mg b.i.d. in the RELY study were 52-275 ng/ml and
74.3-383 ng/ml, respectively.26
Platelet-Derived and Endothelial-Derived Microparticles
Determination
PMP and EMP levels were measured through the direct fluor-
escence method using flow cytometry assay, as previously
described.27,28 Venous blood was drawn into Vacutainer™
CTAD vacuum glass tubes (Becton Dickinson), containing
0.11 M buffered trisodium citrate solution, 15 M theophylline,
3.7 M adenosine and 0.198 M dipyridamole. The blood samples
were centrifuged at room temperature at 1550G for 20 minutes
in order to separate larger morphotic elements. The obtained
supernatant was transferred into Eppendorf tubes, leaving about
200 ml of fluid above the cell line, and the tubes were frozen at -
80C. After thawing, the material was centrifuged on a MiniSpin
Plus centrifuge (Eppendorf, Germany) at room temperature at
13000G, for 2 minutes. From the prepared sample, 100ml of the
supernatant was moved to TruCount tubes (Becton Dickinson,
USA). Characteristic cell markers were used for each type of
MP to evaluate these different types. The sample was labelled
with monoclonal antibodies against CD42b and CD144 (5ml
of each). After thorough mixing of the sample, the material
was incubated for 20 minutes at room temperature in the
dark. 100ml of the diluted (1:10) buffer “Annexin V Binding
Buffer” (the diluted buffer was filtered using a 0.2 mm
Whatman filter) and 5 ml Annexin V FITC were then added
to the sample. The sample was then mixed again and incu-
bated for 10 minutes at room temperature in the dark. After
incubation, 300ml of diluted (1:10) Annexin V Binding Buf-
fer was added. Finally, the prepared samples were analyzed
using the FACSCalibur flow cytometer (Becton Dickinson,
USA).29 The change in PMPs and EMPs (DCD42b and
DC144, respectively) were defined as MP concentrations
after the administration of dabigatran minus the baseline.
The technicians performing these measurements were
blinded to the treatment groups.
Statistical Analysis
The study was powered to have a 90% chance of detecting a 10%
difference in MPs between groups at p ¼ 0.05, based on a pre-
vious study.13 13 patients were required in each group in order to
demonstrate such a difference in MPs. Quantitative variables
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were reported as the mean (+standard deviation) or median
(interquartile range [IQR], where appropriate. The Shapiro-
Wilk test was used to check the normality of distribution. The
quantitative variables were evaluated between groups using the
t-Student test or the Mann-Whitney U test. The Wilcoxon-Sign
test was used to evaluate MPs between and after dabigatran
administration. Moreover, a linear dependence between vari-
ables was tested using Pearson’s correlation or Spearman’s rank
test, as appropriate. In order to identify independent factors
affecting the level of MPs, all clinical and laboratory variables
that showed the association with MPs in the univariate model
(P < 0.15) were included in the multivariate analysis. The models
were adjusted for age and sex. P values <0.05 were considered
statistically significant. Data were analyzed using STATISTICA
13.0 (Statsoft Inc, Tulsa, OK).
Ethics Approval and Consent to Participate
The study was approved by the Jagiellonian University Ethics
Committee (Trial registration No. 122.6120.97.2015; regis-
tered May 28, 2015, http://kbet.cm.uj.edu.pl/), Cracow, Poland.
All procedures performed in the studies involving human par-
ticipants were in accordance with the ethical standards of the
institutional and national research committee.
Results
Patient Characteristics
The study group was comprised of 39 patients with AF (par-
oxysmal n¼ 8 [20.5%]; persistent n¼ 31 [79.5%]) treated with
dabigatran. This includes 28 patients taking a standard dose of
150 mg twice daily (b.i.d.) and 11 patients receiving a reduced
dose of 110 mg b.i.d. Table 1 shows the prevalence of cardio-
vascular risk factors. Most patients (n ¼ 30; 76.9%) were at a
high risk for stroke (CHA2DS2-VASc score 2). Two patients
(5.1%) had a low stroke risk (score of 0; These patients
received anticoagulation before undergoing cardioversion).
One-fifth of patients (n¼ 8; 20.5%) had a high risk of bleeding
(HAS-BLED score 3). Patients who were treated with 150mg
of dabigatran were younger, had a lower CHA2DS2-VASc
score and a higher creatinine clearance compared to those
treated with a dose of 110 mg b.i.d. (Table 1, Suppl. Table 1).
Plasma Concentrations of Anticoagulants
The post-dose plasma concentration of dabigatran was deter-
mined in 24 patients. Seventeen patients (70.8%) had a plasma
drug concentration at the peak range that showed no difference
between 150 mg b.i.d. and 110 mg b.i.d. (70.6% [n ¼ 12] vs.
57.1% [n ¼ 5], respectively, p ¼ 0.53).
Table 1. Baseline Characteristic of Patients.
Overall (n ¼ 39) Dabigatran 110mg (n ¼ 11) Dabigatran 150mg (n ¼ 28) P-value
Age (years) 66.5 + 13.7 76.3 + 10.9 62.7 + 12.9 0.004
Women 14 (35.9) 5 (12.8) 9 (23.1) 0.435
BMI (kg/m2) 30.3 + 5.0 28.9 + 3.7 30.8 + 5.4 0.292
CHA2DS2-VASc score 3.4 + 1.9 4.4 + 1.8 3.0 + 1.9 0.045
HAS-BLED score 1.6 + 1.1 1.9 + 0.7 1.5 + 1.3 0.362
Hypertension 29 (74.4) 9 (23.1) 20 (51.3) 0.504
Diabetes mellitus 11 (28.2) 5 (12.8) 6 (15.4) 0.134
Hypercholesterolemia 34 (87.2) 10 (25.6) 24 (61.5) 0.662
History of smoking 16 (41.0) 5 (12.8) 11 (28.2) 0.725
Coronary artery disease 16 (41.0) 7 (17.9) 9 (23.1) 0.072
Congestive heart failure 14 (35.9) 4 (10.3) 10 (25.6) 0.970
Peripheral artery disease 7 (17.9) 3 (7.7) 4 (10.3) 0.342
Chronic kidney disease grade 3 2 (5.1) 1 (2.6) 1 (2.6) 0.482
Prior stroke/TIA 5 (12.8) 1 (2.6) 4 (10.3) 0.662
History of bleeding 2 (5.1) 1 (2.6) 1 (2.6) 0.482
Treatment
Antiplatelet drugs 6 (15.4) 1 (2.6) 5 (12.8) 0.495
ARB 6 (15.4) 1 (2.6) 5 (12.8) 0.495
Dihydropyridines 9 (23.1) 1 (2.6) 8 (20.5) 0.194
Metformin 9 (23.1) 3 (7.7) 6 (15.4) 0.697
Laboratory parameters
Hb (g/dL) 14.4 + 1.1 13.6 + 0.9 14.7 + 1.0 0.001
PLT (10^3/ml) 229.4 + 66.5 221.0 + 69.8 232.6 + 66.1 0.629
Creatinine (mmol/L) 91.1 + 19.1 90.5 + 21.5 91.3 + 18.4 0.900
ClCr (ml/min) 84.1 + 26.5 67.7 + 23.6 90.8 + 25.0 0.012
Values are presented as, n (%) or mean + standard deviation.
Abbreviations: BMI, body mass index; CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age 75 years, Diabetes, Prior stroke/transient ischemic
attack (TIA)/thromboembolism, Vascular disease, Age 65–74 years, Sex category (female); HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile international normalized ratio (INR), Elderly, Drugs/Alcohol concomitantly; ARB, angiotensin II receptor blockers; Hb,
haemoglobin; PLT, platelet level; ClCr, creatinine clearance according to the Cockcroft-Gault equation.
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Microparticle Plasma Concentrations and Their
Determinants
CD42b. We compared plasma concentrations of PMPs before
and after taking dabigatran.
Patients with PAD had higher levels of CD42b before and
after the administration of dabigatran. A subgroup with a history
of myocardial infarction had higher CD42b levels before admin-
istration of dabigatran, whereas patients treated with angiotensin
II receptor blockers, dihydropyridines and metformin had higher
CD42b levels after anticoagulant administration (Table 2).
CD42b levels before taking anticoagulants positively corre-
lated with the number of pack-years (r ¼ 0.69, p ¼ 0.013).
CD42b levels after taking anticoagulants correlated positively
with the CHA2DS2-VASc score (r ¼ 0.33, p ¼ 0.040) and was
borderline negatively correlated with dabigatran concentra-
tions (r ¼ -0.39, p ¼ 0.060).
After dabigatran administration CD42b increased (median
[IQR] 36.7 [29.4-53.3] vs. 45.6 [32.3-59.5] cells/mL;
p ¼ 0.025) (Figure 1). In patients with coronary artery disease
(CAD) after taking dabigatran we observed a smaller increase
in CD42b compared to patients without CAD (102.4% [60.5-
130.1] vs. 144.6% [101.5-245.4], p ¼ 0.038). Among patients
with peripheral artery disease (PAD), there was a trend toward
higher post-dabigatran CD42b compared to the remainder
of the cohort (179.1% [52.2-272.3] vs. 120.4% [92.2-152.1],
p ¼ 0.158). The concentration of dabigatran correlated nega-
tively with DCD42b (r ¼ -0.47, p ¼ 0.021) (Figure 1).
In the multivariable regression analysis, the independent
predictors of DCD42b were the peak plasma concentration of
dabigatran (HR -0.55; 95% CI [-0.93, -0.16]), CAD (HR -0.41;
95% CI [-0.79, -0.02]; and PAD (HR 0.42; 95% CI [0.07,
0.74]), (R2 ¼ 0.42, Table 3).
CD144. Patients treated with dihydropyridines and metformin
had a higher CD144 count both before and after dabigatran
administration. Those treated with a statin had a higher
CD144 count before dabigatran administration, whereas
patients with PAD and history of stroke/TIA had higher
CD144 after anticoagulant administration (Suppl. Table 2).
CD144 levels after taking anticoagulant correlated positively
with the CHA2DS2-VASc score (r ¼ 0.32, p ¼ 0.044).
CD144 did not increase after taking anticoagulants (17.1
[12.6-19.5] vs. 19.2 [12.5-25.1] cells/mL, p¼ 0.745) (Figure 1).
In a subgroup analysis, a post-dabigatran increase in
CD144 levels was observed in patients with PAD
(149.8% [102.9-367.7] vs. 96.7% [85.7-156.1], remainders,
p ¼ 0.023). The concentration of dabigatran did not correlate
with DCD144 (r ¼ -0.32, p ¼ 0.121) (Figure 1).
12-month follow-up. Neither ischemic stroke nor systemic
thromboembolism were observed during the 12-month
follow-up period. A new thrombus in the left atrial appendage
was revealed in 2 patients with the dabigatran plasma concen-
tration “in the peak range.” There were 2 major bleedings,
including 1 hemorrhagic stroke among patients receiving a
standard dose of dabigatran.
Discussion
This prospective study shows that in AF patients, dabigatran
administration is associated with the release of PMPs (CD42b),
a marker of platelet activation. A negative correlation between
the concentration of dabigatran and DCD42b suggests a harm-
ful effect associated with low doses of this anticoagulant.
Moreover, comorbidities such as PAD and CAD may exert
an antagonistic effect of on the change in CD42b.
Formation of MPs is an essential part of the physiological
coagulation process. Aminophospholipids on the surface of
PMPs and EMPs have a large number of binding sites for
plasma coagulation factors (IXa, VIII, Va and IIa). Therefore,
activation of blood coagulation proteins may occur both on
Table 2. PMP in AF Patients Treated With Dabigatran Before and After Taking an Anticoagulant.
CD42b (number of MP/ml)
before taking anticoagulant after taking anticoagulant
mean + SD P-value mean + SD P-value
CAD (þ) 44.0 + 16.3 0.630 CAD (þ) 46.1 + 36.3 0.207
CAD (-) 40.7 + 23.4 CAD (-) 64.6 + 48.8
History of MI (þ) 66.8 + 12.9 0.009 History of MI (þ) 69.5 + 71.5 0.560
History of MI (-) 39.2 + 19.5 History of Mi (-) 55.6 + 41.8
PAD (þ) 57.9 + 19.6 0.022 PAD (þ) 98.2 + 76.5 0.005
PAD (-) 38.6 + 19.4 PAD (-) 48.0 + 28.8
ARB (þ) 53.9 + 20.2 0.128 ARB (þ) 89.7 + 76.2 0.049
ARB (-) 39.9 + 20.2 ARB (-) 51.0 + 34.8
Dihydropyridines (þ) 53.0 + 16.7 0.068 Dihydropyridines (þ) 88.6 + 65.1 0.013
Dihydropyridines (-) 38.7 + 20.7 Dihydropyridines (-) 47.5 + 32.0
Metformin (þ) 52.8 + 17.3 0.075 Metformin (þ) 89.1 + 65.0 0.011
Metformin (-) 38.8 + 20.7 Metformin (-) 47.3 + 31.8
Abbreviations, see Table 1; CAD, coronary artery disease; PAD, peripheral artery disease; MI, myocardial infarction.
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whole plaques and on MPs.30 Glycoprotein Ib (GPIb, CD42b)
is a component of the GPIb-V-IX complex on platelets, which
allows platelet adhesion and platelet plug formation at sites of
vascular injury. Vascular endothelial cadherin (VE-cadherin,
CD144) is an endothelial-specific adhesion molecule located
at the junctions between endothelial cells. These molecules
maintain and control endothelial cell contacts, and play an
important role in controlling vascular permeability and leuko-
cyte extravasation.31 The mechanism of hemostasis is shown in
Figure 2.
The lack of a need for routine laboratory monitoring is the
primary advantage of NOACs over Vitamin K antagonists.
Dabigatran is one of the most commonly used NOACs in the
antithrombotic management of patients with AF.33 Dabigatran
has a unique mechanism through which it might function as an
anticoagulant. In addition to blocking the catalytic activity of
thrombin, it may displace thrombin from fibrin or platelets,34
and inhibit GPIba-mediated platelet aggregation.35 Despite
this, there are reports36,37 where dabigatran therapy has been
associated with an increase in acute coronary events when
compared with warfarin. The benefits of dabigatran over war-
farin seem to outweigh the small increase in the risk of MI.38 In
addition to its antithrombotic effect, dabigatran has been sug-
gested39 to exert some pro-thrombotic effect due to its fostering
the ligation of thrombin to its high-affinity platelet receptor
(GPIba) in patients with AF. Petzold et al.39 described
Figure 1. Associations between CD42b and CD144 and administration of dabigatran (pre, post, Panels A and B) in patients with atrial fibrillation
(AF). Correlations of DCD42b (Panel C), DCD144 (Panel D) with peak dabigatran concentration in subjects with AF. Values are presented as
median (interquartile range), and black points indicate an outlier.
Table 3. Multivariable Regression Analysis of DCD42b (R2 ¼ 0.42).
Univariate analysis Multivariate analysis
Variable HR (95% CI) P-value HR (95% CI) P-value
Age (years) 0.13 (-0.20, 0.45) 0.441 - -
Peak plasma concentrations of dabigatran (ng/ml) -0.43 (-0.82, -0.19) 0.036 -0.55 (-0.93, -0.16) 0.007
CAD -0.26 (-0.58, 0.06) 0.105 -0.41 (-0.79, -0.02) 0.037
PAD 0.15 (-0.03, 0.69) 0.072 0.42 (0.07, 0.74) 0.019
Previous smoking -0.24 (-0.56, 0.08) 0.139 - -
Abbreviations, see Tables 1, 2.
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increased platelet aggregation in patients with AF treated with
dabigatran compared with those receiving VKA. Siwaponanan
et al. reported an increase in total circulating MP levels, as well
as evidence of elevated endothelial damage and platelet activa-
tion, as demonstrated by the increased PMPs and EMPs levels
in AF patients.13 The use of dabigatran causes suppression of
fibrin formation and thus the formation of thrombi. However,
this drug may lead to platelet activation as seen in the increase
in PMPs, which are markers of platelet activation.
Previous findings have suggested that MPs can play both a
procoagulant role, as well as having a role in anticoagulation.
Tans et al.40 demonstrated that PMPs also possess potent antic-
oagulant functionality. MPs with phosphatidylserine on their
surface are involved in the formation of thrombin, which acti-
vates the C protein involved in the degradation of coagulation
factors Va and VIIIa. The fibrinolytic activity of EMPs is
mainly based on the activity of tissue plasminogen activator
(tPA). The presence of tPA on the surface of MPs increases
plasma plasmin activity.41,42
Choudhury et al. showed evidence of platelet activation
(i.e., high PMPs and sP-selectin levels) in AF patients, but they
suggest that this is likely due to underlying cardiovascular
diseases rather than the arrhythmia per se.19,43 In our study,
both PMPs and EMPs correlated positively with the
CHA2DS2-VASc score after taking an anticoagulant, suggest-
ing an increased thromboembolic risk.
In our study, we observed that the presence of CAD was
associated with a lower increase in CD42b. This may be related
to a higher concentration of CD42b at the baseline in CAD
patients, especially in patients with a history of MI. However,
we also observed a greater increase in CD144 levels in the
subgroup of patients with PAD, which may be associated with
greater endothelial activation after taking dabigatran.
The limitations of our study include the sample size. How-
ever, the number of subjects was sufficient to detect the differ-
ences between the groups, given the results of the power
calculation. Due to a high thromboembolic risk in the real-
life AF population,44 we did not enroll patients with AF and
without an indication for anticoagulant treatment. Despite the
particularly carefully selected study group (numerous exclu-
sion criteria for inclusion in the study), we cannot rule out the
impact of comorbidities on EMPs and PMPs in patients with
AF. In our analyses, we did not take into account the assess-
ment of the effect of microparticle concentration on adverse
Figure 2. Components of hemostasis. Coagulation factors in the bright blue, dark blue and green frames belong to the intrinsic, extrinsic and
common blood coagulation pathways. Black horizontal arrows indicate transformation from inactive to active forms. Red bar-headed lines show
the inhibition of active protease forms and targets of anticoagulants. Black dashed arrows indicate an impact on the process. Abbreviations:
APCþPS, activated protein C þ protein S, AT, antithrombin, Ca2þ-calcium, F, factor, GPIb, glycoprotein Ib, HMWK, high molecular weight
kininogen, PK, plasma prekallikrein, PL, phospholipids, TF, tissue factor, TFPI, tissue factor protease inhibitor, tPA, tissue plasminogen activator,
uPA, urokinase plasminogen activator, VE-cadherin, vascular endothelial cadherin [based on 32].
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events because of too small the 12 month follow-up event rate.
Finally, the mechanisms underlying thrombogenesis in AF are
clearly complex and remain only partially understood, and
therefore further studies are required to evaluate the role of
PMPs and EMPs in the pathophysiology of AF.
Conclusions
In patients with AF, the administration of dabigatran is associ-
ated with an increase in CD42b levels. The release of platelet
microparticles strongly correlates with the concentration of
dabigatran in the blood, suggesting that lower dabigatran con-
centrations are not able to diminish post-drug platelet activa-
tion. This mechanism may potentially lead to paradoxical
thrombosis in AF patients treated with dabigatran. We believe
that larger studies are necessary to evaluate the relationship
between MPs and dabigatran in AF.
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